Search

Your search keyword '"Padmakumar, Priyadharshini"' showing total 4 results
Start Over Author "Padmakumar, Priyadharshini"
4 results on '"Padmakumar, Priyadharshini"'

1. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19

Author

Aaroe, Ashley, Aloia, Thomas A., Andrews, Lee, II, Badami, Kiran K., Baganz, Janna A., Bajwa, Pratibha, Baker, Lori R., Barbosa, Gregory R., Beird, Hannah C., Bourgeois, Matt, Brock, Kristy, Burton, Elizabeth M., Cata, Juan, Chung, Caroline, Cutherell, Michael, Cuenca, John A., Cyr, Pierre B., Dabaja, Bouthaina, Dagher, Hiba, Daniels, Kevin M., Domask, Mary, Draetta, Giulio, Fisher, Sarah, French, Katy Elizabeth, Futreal, Andrew, Gaeta, Maria, Gibbons, Christopher, Godoy, Myrna, Goldstein, Drew, Gunther, Jillian, Hernandez, Cristhiam, Hutcheson, Kate, Jaffray, David, Jin, Jeff, John, Teny Matthew, Kell, Trey, Knafl, Mark, Kothari, Anai, Kwan, Rayson C., Lee, J. Jack, Liao, Yue, Litton, Jennifer, Liu, Alex, McEnery, Kevin W., McGuire, Mary, Musunuru, Tego, Muthu, Mayoora, Nates, Joseph L., Owen, Craig S., Padmakumar, Priyadharshini, Page, Melody, Palaskas, Nicholas, Patel, Jay J., Prabhakaran, Sabitha, Ravi, Vinod, Russell, Ludivine, Sajith, Bilja, Scheet, Paul A., Schmidt, Stephanie, Shaw, Kenna R., Shete, Sanjay, Shoenthal, Daniel P., Stoltenberg, Lessley J., Subbiah, Ishwaria, Suitor, Chuck, Tawbi, Hussein, Thompson, Phillip, Turin, Anastasia, Unni, Samir, Vicknamparampil, Benju, Weber, Max C., Weinstein, John, Williams, Zoe, Woodman, Scott E., Wozny, Mark C., Wu, Carol, Wu, Jia, Yao, James C., Young, Chingyi, Yu, Emily, Zatorski, Steven, Reddy, Dereddi Raja, Botdorf, Joshua, Hanmandlu, Ankit, Wegner, Robert, Crommett, John, Gutierrez, Cristina, Rathi, Nisha, and Abbas, Hussein A.

Published
2023
Full Text
View/download PDF

2. Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.

Author

Qin, Kang, Wang, Kaiwen, Li, Shenduo, Hong, Lingzhi, Padmakumar, Priyadharshini, Waree, Rinsurongkawong, Hubert, Shawna M., Le, Xiuning, Vokes, Natalie, Rai, Kunal, Vaporciyan, Ara, Gibbons, Don L., Heymach, John V., Lee, J. Jack, Woodman, Scott E., Chung, Caroline, Jaffray, David A., Altan, Mehmet, Lou, Yanyan, and Zhang, Jianjun

Subjects
THERAPEUTIC use of antineoplastic agents, DOCETAXEL, PEARSON correlation (Statistics), RESEARCH funding, T-test (Statistics), DATA analysis, IMMUNOTHERAPY, FISHER exact test, DESCRIPTIVE statistics, MULTIVARIATE analysis, MANN Whitney U Test, CHI-squared test, METASTASIS, MONOCLONAL antibodies, IMMUNE checkpoint inhibitors, KAPLAN-Meier estimator, LOG-rank test, DRUG efficacy, RESEARCH, STATISTICS, LUNG cancer, GENETIC mutation, DATA analysis software, CONFIDENCE intervals, DRUG tolerance, PROPORTIONAL hazards models
Abstract

Simple Summary: Docetaxel +/− ramucirumab is now frequently used as the standard chemotherapeutic regimen for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs), regardless of the tumor histology. However, these regimens only lead to short-lived disease control with substantial toxicity, and there is an unmet need for more treatment options in this setting. Our study investigated whether the cancer gene mutation status is associated with clinical benefits from docetaxel +/− ramucirumab by analyzing treatment and outcomes by genomic status. We also explored whether platinum/taxane-based regimens offered a better clinical benefit in this patient population. The results of this study showed that the benefit from docetaxel +/− ramucirumab was not dependent on the cancer gene mutation status. Our exploratory analysis also suggested that platinum-/taxane-based regimens could be reasonable alternative treatment options with better efficacy and comparable tolerability. Docetaxel +/− ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether the cancer gene mutation status was associated with clinical benefits from docetaxel +/− ramucirumab. We also investigated whether platinum/taxane-based regimens offered a better clinical benefit in this patient population. A total of 454 patients were analyzed (docetaxel +/− ramucirumab n = 381 ; platinum/taxane-based regimens n = 73 ). Progression-free survival (PFS) and overall survival (OS) were compared among different subpopulations with different cancer gene mutations and between patients who received docetaxel +/− ramucirumab versus platinum/taxane-based regimens. Among patients who received docetaxel +/− ramucirumab, the top mutated cancer genes included TP53 (n = 167) , KRAS (n = 127) , EGFR (n = 65) , STK11 (n = 32) , ERBB2 (HER2) (n = 26) , etc. None of these cancer gene mutations or PD-L1 expression was associated with PFS or OS. Platinum/taxane-based regimens were associated with a significantly longer mQS (13.00 m, 95% Cl: 11.20–14.80 m versus 8.40 m, 95% Cl: 7.12–9.68 m, LogRank P = 0.019 ) than docetaxel +/− ramcirumab. Key prognostic factors including age, histology, and performance status were not different between these two groups. In conclusion, in patients with metastatic NSCLC who have progressed on platinum doublets and ICIs, the clinical benefit from docetaxel +/− ramucirumab is not associated with the cancer gene mutation status. Platinum/taxane-based regimens may offer a superior clinical benefit over docetaxel +/− ramucirumab in this patient population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19

Author

Reddy, Dereddi Raja, primary, Cuenca, John A., additional, Botdorf, Joshua, additional, Muthu, Mayoora, additional, Hanmandlu, Ankit, additional, Wegner, Robert, additional, Crommett, John, additional, Gutierrez, Cristina, additional, Rathi, Nisha, additional, Sajith, Bilja, additional, Knafl, Mark, additional, Abbas, Hussein A., additional, Woodman, Scott E., additional, Nates, Joseph L., additional, Aaroe, Ashley, additional, Aloia, Thomas A., additional, Andrews, Lee, additional, Badami, Kiran K., additional, Baganz, Janna A., additional, Bajwa, Pratibha, additional, Baker, Lori R., additional, Barbosa, Gregory R., additional, Beird, Hannah C., additional, Bourgeois, Matt, additional, Brock, Kristy, additional, Burton, Elizabeth M., additional, Cata, Juan, additional, Chung, Caroline, additional, Cutherell, Michael, additional, Cyr, Pierre B., additional, Dabaja, Bouthaina, additional, Dagher, Hiba, additional, Daniels, Kevin M., additional, Domask, Mary, additional, Draetta, Giulio, additional, Fisher, Sarah, additional, French, Katy Elizabeth, additional, Futreal, Andrew, additional, Gaeta, Maria, additional, Gibbons, Christopher, additional, Godoy, Myrna, additional, Goldstein, Drew, additional, Gunther, Jillian, additional, Hernandez, Cristhiam, additional, Hutcheson, Kate, additional, Jaffray, David, additional, Jin, Jeff, additional, John, Teny Matthew, additional, Kell, Trey, additional, Kothari, Anai, additional, Kwan, Rayson C., additional, Lee, J. Jack, additional, Liao, Yue, additional, Litton, Jennifer, additional, Liu, Alex, additional, McEnery, Kevin W., additional, McGuire, Mary, additional, Musunuru, Tego, additional, Owen, Craig S., additional, Padmakumar, Priyadharshini, additional, Page, Melody, additional, Palaskas, Nicholas, additional, Patel, Jay J., additional, Prabhakaran, Sabitha, additional, Ravi, Vinod, additional, Russell, Ludivine, additional, Scheet, Paul A., additional, Schmidt, Stephanie, additional, Shaw, Kenna R., additional, Shete, Sanjay, additional, Shoenthal, Daniel P., additional, Stoltenberg, Lessley J., additional, Subbiah, Ishwaria, additional, Suitor, Chuck, additional, Tawbi, Hussein, additional, Thompson, Phillip, additional, Turin, Anastasia, additional, Unni, Samir, additional, Vicknamparampil, Benju, additional, Weber, Max C., additional, Weinstein, John, additional, Williams, Zoe, additional, Wozny, Mark C., additional, Wu, Carol, additional, Wu, Jia, additional, Yao, James C., additional, Young, Chingyi, additional, Yu, Emily, additional, and Zatorski, Steven, additional

Published
2023
Full Text
View/download PDF

4. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19

Author

Reddy, Dereddi Raja, Cuenca, John A., Botdorf, Joshua, Muthu, Mayoora, Hanmandlu, Ankit, Wegner, Robert, Crommett, John, Gutierrez, Cristina, Rathi, Nisha, Sajith, Bilja, Knafl, Mark, Abbas, Hussein A., Woodman, Scott E., Nates, Joseph L., Aaroe, Ashley, Aloia, Thomas A., Andrews, Lee, Badami, Kiran K., Baganz, Janna A., Bajwa, Pratibha, Baker, Lori R., Barbosa, Gregory R., Beird, Hannah C., Bourgeois, Matt, Brock, Kristy, Burton, Elizabeth M., Cata, Juan, Chung, Caroline, Cutherell, Michael, Cuenca, John A., Cyr, Pierre B., Dabaja, Bouthaina, Dagher, Hiba, Daniels, Kevin M., Domask, Mary, Draetta, Giulio, Fisher, Sarah, French, Katy Elizabeth, Futreal, Andrew, Gaeta, Maria, Gibbons, Christopher, Godoy, Myrna, Goldstein, Drew, Gunther, Jillian, Hernandez, Cristhiam, Hutcheson, Kate, Jaffray, David, Jin, Jeff, John, Teny Matthew, Kell, Trey, Knafl, Mark, Kothari, Anai, Kwan, Rayson C., Lee, J Jack, Liao, Yue, Litton, Jennifer, Liu, Alex, McEnery, Kevin W., McGuire, Mary, Musunuru, Tego, Muthu, Mayoora, Nates, Joseph L., Owen, Craig S., Padmakumar, Priyadharshini, Page, Melody, Palaskas, Nicholas, Patel, Jay J., Bajwa, Pratibha, Ravi, Vinod, Russell, Ludivine, Sajith, Bilja, Scheet, Paul A., Schmidt, Stephanie, Shaw, Kenna R., Shete, Sanjay, Shoenthal, Daniel P., Stoltenberg, Lessley J., Subbiah, Ishwaria, Suitor, Chuck, Tawbi, Hussein, Thompson, Phillip, Turin, Anastasia, Unni, Samir, Vicknamparampil, Benju, Weber, Max C., Weinstein, John, Williams, Zoe, Woodman, Scott E., Wozny, Mark C., Wu, Carol, Wu, Jia, Yao, James C., Young, Chingyi, Yu, Emily, and Zatorski, Steven

Abstract

There is scant information on the clinical progression, end-of-life decisions, and cause of death of cancer patients diagnosed with COVID-19. Therefore, we conducted a case series of patients admitted to a comprehensive cancer center who did not survive their hospitalization. To determine the cause of death of death three board-certified intensivists reviewed the electronic medical records. Concordance regarding cause of death was calculated. Discrepancies were resolved through a joint case-by-case review and discussion between the three reviewers. During the study period, 551 patients with cancer and COVID-19 were admitted to a dedicated specialty unit; among them, 61 (11.6%) were non-survivors. Among non-survivors, thirty-one (51%) patients had hematological, and 29 (48%) had undergone cancer-directed chemotherapy within 3 months before admission. The median time to death was 15 days (95% CI, 11.8-18.2). There were no differences in time to death by cancer category or cancer treatment intent. The majority of decedents (84%) had full code status at admission; however, 53 (87%) had a Do-Not-Resuscitate order at the time of death. Most deaths were deemed to be COVID-19-related (88.5%). The concordance between the reviewers for the cause of death was 78.7%. In contrast to the belief that COVID-19 decedents perish due to their comorbidities, in our study only one of every ten patients died of cancer–related causes. Full-scale interventions were offered to all patients irrespective of oncologic treatment intent. However, most decedents in this population preferred care with non-resuscitative measures rather than full support at the end of life.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results